First Time Loading...

eFFECTOR Therapeutics Inc
NASDAQ:EFTR

Watchlist Manager
eFFECTOR Therapeutics Inc Logo
eFFECTOR Therapeutics Inc
NASDAQ:EFTR
Watchlist
Price: 1.78 USD -5.82%
Updated: Apr 19, 2024

Intrinsic Value

EFTR's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). [ Read More ]

The intrinsic value of one EFTR stock under the Base Case scenario is 4.98 USD. Compared to the current market price of 1.78 USD, eFFECTOR Therapeutics Inc is Undervalued by 64%.

Key Points:
EFTR Intrinsic Value
Base Case
4.98 USD
Undervaluation 64%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
eFFECTOR Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EFTR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
eFFECTOR Therapeutics Inc

Provide an overview of the primary business activities
of eFFECTOR Therapeutics Inc.

What unique competitive advantages
does eFFECTOR Therapeutics Inc hold over its rivals?

What risks and challenges
does eFFECTOR Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in eFFECTOR Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for eFFECTOR Therapeutics Inc.

Provide P/S
for eFFECTOR Therapeutics Inc.

Provide P/E
for eFFECTOR Therapeutics Inc.

Provide P/OCF
for eFFECTOR Therapeutics Inc.

Provide P/FCFE
for eFFECTOR Therapeutics Inc.

Provide P/B
for eFFECTOR Therapeutics Inc.

Provide EV/S
for eFFECTOR Therapeutics Inc.

Provide EV/GP
for eFFECTOR Therapeutics Inc.

Provide EV/EBITDA
for eFFECTOR Therapeutics Inc.

Provide EV/EBIT
for eFFECTOR Therapeutics Inc.

Provide EV/OCF
for eFFECTOR Therapeutics Inc.

Provide EV/FCFF
for eFFECTOR Therapeutics Inc.

Provide EV/IC
for eFFECTOR Therapeutics Inc.

Show me price targets
for eFFECTOR Therapeutics Inc made by professional analysts.

What are the Revenue projections
for eFFECTOR Therapeutics Inc?

How accurate were the past Revenue estimates
for eFFECTOR Therapeutics Inc?

What are the Net Income projections
for eFFECTOR Therapeutics Inc?

How accurate were the past Net Income estimates
for eFFECTOR Therapeutics Inc?

What are the EPS projections
for eFFECTOR Therapeutics Inc?

How accurate were the past EPS estimates
for eFFECTOR Therapeutics Inc?

What are the EBIT projections
for eFFECTOR Therapeutics Inc?

How accurate were the past EBIT estimates
for eFFECTOR Therapeutics Inc?

Compare the revenue forecasts
for eFFECTOR Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of eFFECTOR Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of eFFECTOR Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of eFFECTOR Therapeutics Inc compared to its peers.

Compare the P/E ratios
of eFFECTOR Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing eFFECTOR Therapeutics Inc with its peers.

Analyze the financial leverage
of eFFECTOR Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for eFFECTOR Therapeutics Inc.

Provide ROE
for eFFECTOR Therapeutics Inc.

Provide ROA
for eFFECTOR Therapeutics Inc.

Provide ROIC
for eFFECTOR Therapeutics Inc.

Provide ROCE
for eFFECTOR Therapeutics Inc.

Provide Gross Margin
for eFFECTOR Therapeutics Inc.

Provide Operating Margin
for eFFECTOR Therapeutics Inc.

Provide Net Margin
for eFFECTOR Therapeutics Inc.

Provide FCF Margin
for eFFECTOR Therapeutics Inc.

Show all solvency ratios
for eFFECTOR Therapeutics Inc.

Provide D/E Ratio
for eFFECTOR Therapeutics Inc.

Provide D/A Ratio
for eFFECTOR Therapeutics Inc.

Provide Interest Coverage Ratio
for eFFECTOR Therapeutics Inc.

Provide Altman Z-Score Ratio
for eFFECTOR Therapeutics Inc.

Provide Quick Ratio
for eFFECTOR Therapeutics Inc.

Provide Current Ratio
for eFFECTOR Therapeutics Inc.

Provide Cash Ratio
for eFFECTOR Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for eFFECTOR Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for eFFECTOR Therapeutics Inc?

What is the current Free Cash Flow
of eFFECTOR Therapeutics Inc?

Financials

Balance Sheet Decomposition
eFFECTOR Therapeutics Inc

Current Assets 19.8m
Cash & Short-Term Investments 18.4m
Other Current Assets 1.5m
Non-Current Assets 706k
PP&E 193k
Other Non-Current Assets 513k
Current Liabilities 25.8m
Accounts Payable 2.3m
Accrued Liabilities 4.1m
Other Current Liabilities 19.4m
Non-Current Liabilities 543k
Other Non-Current Liabilities 543k
Efficiency

Earnings Waterfall
eFFECTOR Therapeutics Inc

Revenue
0 USD
Operating Expenses
-33.8m USD
Operating Income
-33.8m USD
Other Expenses
-2m USD
Net Income
-35.8m USD

Free Cash Flow Analysis
eFFECTOR Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EFTR Profitability Score
Profitability Due Diligence

eFFECTOR Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
Negative Operating Income
Negative Net Income
39/100
Profitability
Score

eFFECTOR Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

EFTR Solvency Score
Solvency Due Diligence

eFFECTOR Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
32/100
Solvency
Score

eFFECTOR Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EFTR Price Targets Summary
eFFECTOR Therapeutics Inc

Wall Street analysts forecast EFTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EFTR is 11.22 USD with a low forecast of 10.1 USD and a high forecast of 12.6 USD.

Lowest
Price Target
10.1 USD
467% Upside
Average
Price Target
11.22 USD
530% Upside
Highest
Price Target
12.6 USD
608% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EFTR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EFTR Price
eFFECTOR Therapeutics Inc

1M 1M
-85%
6M 6M
-87%
1Y 1Y
-82%
3Y 3Y
-99%
5Y 5Y
-99%
10Y 10Y
-99%
Annual Price Range
1.78
52w Low
1.78
52w High
34.75
Price Metrics
Average Annual Return -56.08%
Standard Deviation of Annual Returns 54.43%
Max Drawdown -100%
Shares Statistics
Market Capitalization 6.6m USD
Shares Outstanding 3 687 310
Percentage of Shares Shorted 9.44%

EFTR Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

eFFECTOR Therapeutics Inc Logo
eFFECTOR Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

6.6m USD

Dividend Yield

0%

Description

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California and currently employs 13 full-time employees. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The company uses selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The firm's lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an inhibitor of programed cell death protein 1 (PD-1) in a randomized Phase IIb clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase I/II clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Contact

CALIFORNIA
Solana Beach
142 North Cedros Avenue, Suite B, Suite A
+18589258215.0
https://effector.com/

IPO

2021-01-08

Employees

13

Officers

CEO, President & Director
Dr. Stephen T. Worland Ph.D.
Chief Financial Officer
Mr. Michael Byrnes M.B.A.
Chief Medical Officer
Dr. Douglas Warner M.D.
Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D.

See Also

Discover More
What is the Intrinsic Value of one EFTR stock?

The intrinsic value of one EFTR stock under the Base Case scenario is 4.98 USD.

Is EFTR stock undervalued or overvalued?

Compared to the current market price of 1.78 USD, eFFECTOR Therapeutics Inc is Undervalued by 64%.